VERTEX PHARMACEUTICALS INC / MA (VRTX) vs. GENERAL ELECTRIC CO (GE) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

VERTEX PHARMACEUTICALS INC / MA (VRTX) vs. GENERAL ELECTRIC CO (GE) Stock Comparison & Valuation | Edwyn

Updated 2026-07-22 11:28 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

VRTX screens as a premium-quality business versus GE on margins and leverage, but the valuation case is mixed because the stock already trades above GE-implied P/E value and well above DCF estimates.

Actionable Takeaway

If you believe VRTX can sustain its premium margins and justify a valuation closer to GE-implied P/E case rather than the DCF band, then holding or adding makes sense because its balance sheet and profitability are materially stronger than GE's; otherwise, the current price already looks stretched versus DCF and only moderately supported by history.

VRTX's current price of $482.00 sits below the P/E implied price of $641.22, suggesting 33.0% upside on that framework. However, the stock also looks expensive versus DCF and only modestly supported by its historical trading band, so the relative valuation signal is not one-directional.

Supporting Metrics

Key Risks

VRTX is trading well above the DCF range of $140.97-$190.72, which raises downside risk if growth or multiple support weakens.
VRTX's Piotroski F-Score of 5/9 suggests only moderate fundamental momentum, not a clear high-quality confirmation.
VRTX's valuation remains elevated on sales and EBITDA multiples, with P/S at 10.2x and EV/EBITDA at 24.3x despite slower revenue growth of 8.9% versus GE's 18.5%.